Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.


First Half 2026 Recap: Nephrology

The phase 3 TURING trial found rituximab slashed relapse rates in adults with minimal change disease and FSGS, offering a steroid-sparing alternative.


Kidney Compass: Rituximab Cuts Relapse Risk in MCD, FSGS in TURING Trial

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

How Sparsentan is Reshaping Care for Patients With FSGS, With George Vasquez Rios, MD

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.

Interpreting Sparsentan’s Proteinuria Benefits Despite Missed eGFR Outcomes

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data. 

5 Nephrology Headlines You Missed in April 2026

Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

A DUPLEX study investigator explains the data behind sparsentan's approval by the FDA. 

Why Sparsentan’s FDA Approval Marks a Turning Point in FSGS, With Howard Tratchman, MD

FDA fully approves sparsentan for FSGS, offering the first oral non-immunosuppressive option that targets podocyte injury and cuts proteinuria.

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

An expert shares his perspective on emerging targets and precision strategies for podocyte injury in glomerular disease. 


Emerging Targets in Podocyte Injury Signal Shift in Glomerular Disease Treatment, With John Cijiang He, MD, PhD

Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 